

AI in Clinical Research: 1 Platform for 30+ Fragmented Tools
Dr. Harsha Rajasimha is a serial entrepreneur and the Founder and CEO of Jeeva Clinical Trials, an AI-ready unified platform that supports the clinical trial process from protocol design strategy to database lock. Jeeva serves biopharma sponsors, CROs, academic medical centers, research sites, and patients. He is also Founder and Executive Chairman of IndoUSrare, which fosters rare disease collaboration across the US, India, and globally through its annual Indo US Bridging RARE Summit and Abbey Meyers Khushi Bridging RARE Awards Gala. A postdoctoral data scientist trained at NIH and FDA, Harsha brings 20+ years of precision medicine data research experience across academia, federally funded research, biopharma R&D consulting, and multiple startups. He holds an M.S. in Computer Science and a Ph.D. in Genetics, Bioinformatics and Computational Biology from Virginia Tech, and has maintained an academic affiliation with George Mason University since 2012. He has authored 20+ publications, book chapters, and patents, and was named to India Abroad's Impact 100 list of Indian Americans in 2025. In this episode… In this episode of Lessons from the Leap, host Ghazenfer Mansoor, CEO of Technology Rivers, known for AI, SaaS, and HIPAA-compliant HealthTech development, and author of Beyond the Download, sits down with Dr. Harsha Rajasimha, founder and CEO of Jeeva Clinical Trials and founder of the nonprofit IndoUSrare. Harsha made the leap from NIH and FDA trained data scientist and pharma consultant to founder of a unified, AI-powered platform built to replace the fragmented tools that slow down drug development. That shift became personal in 2012, when one of his three children was born with a rare disease, and his professional and personal experience converged into one mission: speeding up therapies for the 95 percent of rare diseases that still have no approved treatment. Harsha explains why clinical trials still run on at least thirty disconnected tools and systems, and how Jeeva pivoted once large language models matured. The team had already built a unified platform on a modern stack in AWS, and then added AI agents on top. One of those is Clintelligence, which analyzes about 600,000 past trials on clinicaltrials.gov to find the most similar studies by disease area, geography, phase, and modality, then flags costly protocol mistakes before a trial begins. Once a trial is running, AI agents check each new data entry against a patient's history in real time, catching errors like an age recorded as 5 one month and 15 the next. It's a practical look at AI in clinical research doing work that no human team could do at that scale. The bigger lesson reaches well beyond clinical trials. Harsha is candid that no AI platform is free of hallucinations, and that success depends on people, process, and technology together, not technology alone. For founders building in regulated healthcare, the conversation makes a strong case for keeping humans in the loop, building for compliance and electronic data from day one, and confirming product-market fit before going too far. It also shows why a single platform can do what a stack of point solutions never will.


















